Go Back   Medical Educational Web > Medical news (researches and texts) > Dermatology
FAQ Members List Social Groups Calendar Search Today's Posts Mark Forums Read

Dermatology Dermatology discussion forum

Untitled Document

FDA Approves Phase I Clinical Trial Of Topaz Pharmaceuticals' New Head Lice Treatment

Topaz Pharmaceuticals LLC, a pharmaceutical company dedicated to the health and well being of children, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational new

Reply
 
Thread Tools Rate Thread Display Modes

Old 07-21-2007, 09:29 PM   post no: 1
Admin
Administrator





Admin is offline



 From his posts
 



Default FDA Approves Phase I Clinical Trial Of Topaz Pharmaceuticals' New Head Lice Treatment



Topaz Pharmaceuticals LLC, a pharmaceutical company dedicated to the health and well being of children, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug application; allowing Topaz to begin clinical trials of the company's topical solution for the treatment of head lice.

The Topaz product is designed to give healthcare professionals a new choice for the treatment of head lice infestations - it will provide a naturally derived treatment that is lethal to lice and nits, yet safe to children and adults. Between 6 and 12 million children are affected by head lice in the United States each year. In many cases, the children with head lice are dismissed from school and not allowed to return until they are declared "lice free" -- impacting parents and children alike.

"This IND approval and the entry of our first subjects into clinical trials bring us closer to a significant milestone in the treatment of head lice," said Nick Spring, Topaz Pharmaceuticals president and chief executive officer. "Current treatments on the market are either becoming less effective because of lice resistance or contain potentially hazardous substances. We remain confident and optimistic that the Topaz solution will be proven safe and effective in subsequent trials, and will eventually help alleviate the frustration, inconvenience and social stigma associated with head lice."

Topaz Pharmaceuticals LLC is a start-up company, which initially benefited from support provided by the Ben Franklin Technology Partners of Southeast Pennsylvania, who develops and markets pediatric medicines. The company expects to develop additional indications covering other parasitic insects affecting human health. Topaz Pharmaceuticals is developing a completely novel and kid friendly formulation of a naturally derived, quick acting ingredient which is lethal to head and body lice. For more information about Topaz Pharmaceuticals, LLC please visit http://www.topazpharma.com.



Topaz Pharmaceuticals LLC
http://www.topazpharma.com













  Reply With Quote
Reply

Bookmarks

« Bioengineered Skin Substitutes Set To Approach 500 Million Dollars By The End Of The Decade | Scleroderma Outlook Improves As Survival Increases »
Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Opko Health Initiates Phase 3 Trial Of Bevasiranib For The Treatment Of AMD Admin Ophthalmology: Eye Physicians & Surgeons 0 07-16-2007 02:52 PM
NeurogesX Completes Enrollment In Phase 3 Clinical Trial For Postherpetic Neuralgia Admin Pain Medicine 0 07-09-2007 08:29 PM
Children Suffering From Vernal Keratoconjunctivitis - Results Of Pivotal Phase III Clinical Trial Wi Admin Ophthalmology: Eye Physicians & Surgeons 0 07-02-2007 04:17 PM
Lev Pharmaceuticals Reports Positive Results In Pivotal Phase III Trial For Admin Dermatology 0 03-31-2007 06:04 AM